Learning Objectives:

1.  Current and evolving therapeutic landscape in metastatic, castrate-resistant prostate cancer (mCRPC).

2.  Immunotherapy in mCRPC and related mechanisms of resistance

3.  Therapeutic strategies to enhance immune-responsiveness in prostate cancer

Session date: 
08/23/2021 - 12:00pm to 1:00pm CDT
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Akash Patnaik, MD, PhD, MMSc